Novel Use of Restasis and PROSE Devices
NCT04735510
·
clinicaltrials.gov ↗
PHASE3
Phase
WITHDRAWN
Status
OTHER
Sponsor class
Stopped
study redesigned
Conditions
Ocular Surface Disease
Interventions
DRUG:
cyclosporine ophthalmic emulsion 0.05%
Sponsor
Boston Sight